Genmab A/S (NASDAQ:GMAB), a Danish biotechnology company specializing in the development and commercialization of antibody therapies for cancer treatment, is making headlines with its recent strategic move to acquire Merus N.V. (NASDAQ:MRUS), a Dutch biotechnology firm, for $97 per share in an all-cash transaction valued at approximately $8 billion. This acquisition is expected to enhance Genmab's oncology portfolio significantly.
On September 29, 2025, Jonathan Chang from Leerink Partners set a price target of $34 for GMAB, while the stock was trading at $29.16. This suggests a potential increase of about 16.61%. Currently, GMAB's stock price is $29.33, reflecting a slight increase of 0.89% with a change of $0.26. The stock has traded between $28.36 and $29.34 today.
The acquisition of Merus includes its late-stage asset, petosemtamab, which is in Phase 3 development. This addition aligns with Genmab's expertise in antibody therapy development and is expected to accelerate its transition to a wholly owned model. The deal is anticipated to close by early in the first quarter of 2026, supporting Genmab's sustained growth into the next decade.
Following the acquisition, Genmab will have four proprietary programs ready to drive multiple new drug launches. This strategic move is expected to diversify Genmab's revenue streams and strengthen its position in the pharmaceutical industry. The company's market capitalization is approximately $18.51 billion, with a trading volume of 5.03 million shares on the NASDAQ exchange.
Merus' stock has surged by 38% following the acquisition announcement, highlighting the market's positive response to the deal. Over the past year, GMAB has reached a high of $29.52 and a low of $17.24, indicating a strong recovery and growth potential. This acquisition is a significant step for Genmab in expanding its capabilities in cancer treatment.
